Stefanie Pederiva
Overview
Explore the profile of Stefanie Pederiva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hofheinz R, Anchisi S, Grunberger B, Derigs H, Zahn M, Geffriaud-Ricouard C, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884583
Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of...
2.
Siebenhuner A, De Dosso S, Helbling D, Astaras C, Szturz P, Moosmann P, et al.
Oncol Res Treat
. 2021 Aug;
44(9):485-494.
PMID: 34350899
Background: Gastric cancer is a leading cause of cancer-related deaths worldwide. Several treatment possibilities have been investigated, but only a few show clinically meaningful results. Summary: Systemic treatment options for...
3.
Tyriakidis K, Stadlmann S, Pederiva S
Case Rep Oncol
. 2021 Mar;
14(1):365-370.
PMID: 33776730
Small-cell carcinoma of the pancreas (PSCC) is a highly aggressive neoplasia with a dismal prognosis. It is extremely rare, with only a few cases reported in the literature. There is...
4.
Schwotzer R, Manz M, Pederiva S, Waibel C, Caspar C, Lerch E, et al.
Hematol Oncol
. 2019 Sep;
37(5):595-600.
PMID: 31486522
Daratumumab, an anti-CD38 antibody, is effective in AL amyloidosis with low tumor burden. Data of daratumumab treatment in patients with AL amyloidosis but high tumor burden (≥10% bone marrow plasma...
5.
Rothschild S, Betticher D, Zenhausern R, Anchisi S, Von Moos R, Pless M, et al.
Cancer Chemother Pharmacol
. 2019 Aug;
84(4):881-889.
PMID: 31444619
Purpose: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer...
6.
Mey U, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, et al.
Br J Haematol
. 2016 Dec;
176(5):770-782.
PMID: 27983764
The combination of lenalidomide (Revlimid , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients...
7.
Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, et al.
Swiss Med Wkly
. 2012 Feb;
142:w13511.
PMID: 22290632
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than...
8.
Hitz F, Ketterer N, Lohri A, Mey U, Pederiva S, Renner C, et al.
Swiss Med Wkly
. 2011 Aug;
141:w13247.
PMID: 21815111
Follicular lymphoma is a slow-growing disease exhibiting a heterogeneous clinical course, with a subset of patients experiencing a rapid disease course in the first two years and some developing disease...
9.
Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F, et al.
Oncology
. 2011 May;
80(1-2):29-33.
PMID: 21606661
Objectives: While oral anticancer treatment has increased the convenience for patients with no risk of venous access complications compared to intravenous drug administration, a high level of compliance cannot always...
10.
Ruhstaller T, Templeton A, Ribi K, Schuller J, Borner M, Thierstein S, et al.
Onkologie
. 2010 May;
33(5):222-8.
PMID: 20502056
Background: There is no standard treatment for patients with locally advanced esophageal carcinoma without systemic metastasis in whom surgery is no longer considered a reasonable option. Patients And Methods: Patients...